Skip to main content

PnuBioVax™: next-generation vaccine for a personalised and effective immune response against Streptococcus pneumoniae.


Pneumococcal disease, caused by the pathogenic bacteria Streptococcus pneumoniae, is a major cause of mortality in the young and elderly. In Europe, it is responsible for 230,000 annual deaths and an economic burden of € 10B annually. Due to the high cost of the current vaccines, rates of infant disease and death are even higher in developing countries, accounting for 1.6M deaths per year. The introduction of pneumococcal vaccines in Europe over the 20th century was pivotal in the reduction of pneumococcal pneumonia cases by 31%. Despite these good results, vaccine efficiency is now decreasing due to the adaptation of S. pneumoniae to the existing vaccines, but also due to its growing antibiotic resistance.

ImmunoBiology’s (ImmBio) platform technology has been used to create a pneumococcal vaccine called PnuBioVax™ (PBV) that aims to address the burden of the disease by offering protection against 100% of the pneumococcal strains. As a result of low manufacturing costs (<€ 1), PBV could become a game changer in the combat of the disease, facilitating its adoption in developing countries. The manufacturing cost of PBV represents a reduction of >95% compared to PCV13, the market leader, estimated at € 20. The vaccine has already been tested in humans, demonstrating its safety and effectiveness.

ImmBio is an innovative company, established in 1999 in the UK, which develops state-of-the-art vaccines using the ImmBioVax™ (IBV) vaccine platform technology. To date, ImmBio has raised circa € 10M in grants and awards. These funds, allowed the company to take the IBV technology from concept to clinical readiness products. The proposed work in Phase 1 of the SME instrument fits into their overall plan to reach the market by contributing to the financial resources needed to complete PBV’ clinical studies and ensure market uptake.

Field of science

  • /medical and health sciences/health sciences/public and environmental health/epidemics prevention/immunisation
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/antibiotic resistance
  • /social sciences/sociology/demography/mortality
  • /social sciences/economics and business/business and management/commerce

Call for proposal

See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1


Babraham Research Campus Building 260
CB22 3AT Cambridge
United Kingdom
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000